Adams Revenue Grows 11% As Mucinex Sales Shift Toward Line Extensions
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics' net sales grew 11 percent to $84 million in its latest quarter as sales of single-ingredient Mucinex were cannibalized by newer extensions in the product line